Healthcare Services

Global Viral Vector-Based Gene Therapy Industry Trends and Market Growth Forecast for 2026–2030

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Viral Vector-Based Gene Therapy Market Expected To Change Between 2026 And 2030?

The viral vector-based gene therapy market has experienced substantial growth recently. This market is projected to expand from $6.77 billion in 2025 to $7.93 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 17.2%. The historical expansion of this market stems from advancements in molecular biology research, a greater understanding of genetic disorders, initial positive outcomes in clinical trials for viral vector therapies, the development of orphan drug programs, and the presence of various viral vector platforms.

The market for viral vector-based gene therapy is projected to experience substantial expansion over the upcoming years. By 2030, its size is anticipated to reach $14.81 billion, showing a compound annual growth rate (CAGR) of 16.9%. This projected growth during the forecast period is attributable to several factors, including the increasing number of gene therapy product approvals, a surge in investment for rare disease treatments, the broadening of precision medicine initiatives, the expanding use of personalized healthcare, and ongoing advancements in vector engineering technologies. Key trends anticipated within this period encompass the increasing acceptance of targeted gene therapies, the evolving development of personalized treatment methods, the expansion of clinical trials for rare diseases, a heightened focus on the long-term effectiveness of therapies, and a stronger emphasis on the safety and performance of vectors.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30431&type=smp

What Drivers Are Expected To Influence The Viral Vector-Based Gene Therapy Market During The Forecast Period?

The expanding occurrence of genetic disorders is anticipated to fuel the expansion of the viral vector-based gene therapy market moving ahead. These conditions stem from alterations or mutations in DNA, which may be inherited or arise spontaneously, impacting an individual’s health, development, or physiological functions. The growing incidence of genetic illnesses is attributable to heightened public awareness and breakthroughs in diagnostic tools, facilitating earlier and more precise identification of conditions that were previously undiagnosed. Viral vector-based gene therapy improves the management of genetic diseases through its ability to deliver therapeutic genes with precision, rendering it highly suitable for addressing inherited conditions. This approach slows disease progression by facilitating the accurate and enduring correction of genetic flaws, thereby enhancing patient results and overall quality of life. As an illustration, in April 2025, the International Diabetes Federation (IDF), a non-profit organization based in Belgium, reported that roughly 589 million individuals had diabetes in 2024, with forecasts indicating this figure will climb to 853 million by 2050. Consequently, the expanding occurrence of genetic diseases is a key factor propelling the growth of the viral vector-based gene therapy market.

How Is The Viral Vector-Based Gene Therapy Market Structured Across Different Segments?

The viral vector-based gene therapy market covered in this report is segmented –

1) By Vector Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors

2) By Delivery Method: Intravenous Injection, Intrathecal Injection, Intramuscular Injection, Subcutaneous Injection, Topical

3) By Application: Oncology, Genetic Disorders, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Other Applications

4) By End-User: Hospitals, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Adenoviral Vectors: Human Adenovirus Serotype Five, Human Adenovirus Serotype Two, Canine Adenovirus

2) By Adeno-Associated Viral Vectors: Adeno-Associated Virus Serotype One, Adeno-Associated Virus Serotype Two, Adeno-Associated Virus Serotype Five, Adeno-Associated Virus Serotype Eight, Other Adeno-Associated Viruses

3) By Lentiviral Vectors: Human Immunodeficiency Virus One, Human Immunodeficiency Virus Two

4) By Retroviral Vectors: Gammaretrovirus, Alpharetrovirus, Spumaretrovirus, Other Retroviruses

What Key Trends Are Influencing The Development Of The Viral Vector-Based Gene Therapy Market?

Leading companies in the viral vector-based gene therapy market are concentrating on establishing advanced platforms, such as integrated manufacturing platforms, to improve efficiency, increase reliability, and decrease the cost and time involved in therapy production. Integrated manufacturing platforms denote extensive systems that streamline the entire process of creating gene therapies, from vector conception to the final product, by utilizing standardized, high-yield methods. For example, in October 2024, Forge Biologics Holdings LLC, a US-based biotechnology company, introduced the FUEL AAV Manufacturing Platform. This is a proprietary, suspension-based manufacturing system engineered to offer significant productivity and scalability. It incorporates a fully integrated plasmid system and optimized processes, which enable robust and consistent production of adeno-associated viral (AAV) vectors for gene therapies, thereby quickening developer timelines from the research stage to clinical trials.

Which Major Players Dominate The Viral Vector-Based Gene Therapy Market?

Major companies operating in the viral vector-based gene therapy market are F. Hoffmann-La Roche AG, Novartis AG, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Inc., Rocket Pharmaceuticals Inc., PTC Therapeutics Inc., 4D Molecular Therapeutics Inc., Editas Medicine Inc., Regenxbio Inc., Oxford Biomedica plc, MeiraGTx Holdings plc, Voyager Therapeutics Inc., Solid Biosciences Inc., Sangamo Therapeutics Inc., Adverum Biotechnologies Inc., Passage Bio Inc., Dyno Therapeutics Inc., uniQure N.V., Bluebird Bio Inc.

Read the full viral vector-based gene therapy market report here:

https://www.thebusinessresearchcompany.com/report/global-viral-vector-based-gene-therapy-market-report

Which Region Is Forecast To Lead The Viral Vector-Based Gene Therapy Market In Terms Of Market Size?

North America was the largest region in the viral vector-based gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector-based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Viral Vector-Based Gene Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30431&type=smp

Browse Through More Reports Similar to the Global Viral Vector-Based Gene Therapy Market 2026, By The Business Research Company

Genes Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Antiviral Combination Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Oral Expectorant Global Market Report

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795